Shares of Alembic Pharmaceuticals saw a sharp uptick of 2.38% on December 20, 2024, trading at ₹1,072.75, following the company’s announcement of receiving final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Divalproex Sodium Delayed-Release Capsules USP, 125 mg.
Key Details:
- Therapeutic Use: Approved for treating various seizure types, the drug will serve as a cost-effective generic alternative to Depakote Sprinkle Capsules by AbbVie Inc.
- Market Size: The drug represents a $61.1 million market opportunity in the U.S. for the 12 months ending September 2024, as per IQVIA.
- Approval Milestone: Alembic now boasts a total of 220 USFDA ANDA approvals, further solidifying its position in the global pharmaceutical market.
Alembic Pharma Share Price history
| Day | Open | Close | Change % |
|---|---|---|---|
|
Thu, Dec 19 2024
|
₹1,046.05
|
₹1,047.80
|
-0.80%
|
|
Wed, Dec 18 2024
|
₹1,031.00
|
₹1,056.20
|
|
|
Tue, Dec 17 2024
|
₹1,055.60
|
₹1,035.40
|
-1.91%
|
|
Mon, Dec 16 2024
|
₹1,046.10
|
₹1,055.60
|
-0.61%
|
|
Fri, Dec 13 2024
|
₹1,038.60
|
₹1,062.05
|
|
|
Thu, Dec 12 2024
|
₹1,094.10
|
₹1,046.00
|
-4.21%
|
|
Wed, Dec 11 2024
|
₹1,100.50
|
₹1,091.95
|
-1.15%
|
|
Tue, Dec 10 2024
|
₹1,105.05
|
₹1,104.60
|
|
About Alembic Pharmaceuticals:
Established in 1907, Alembic Pharmaceuticals Limited is a leader in the healthcare sector, renowned for its extensive product portfolio and global research-driven operations. With state-of-the-art manufacturing facilities, the company continues to expand its footprint in both generic and branded drug segments.
